OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Berdeja on the Current Landscape of BCMA-Directed Therapies in Multiple Myeloma

October 7th 2023

Jesus Berdeja, MD, discusses the BCMA-directed CAR T-cell therapies and bispecific antibodies available for patients with multiple myeloma.

Dr Harpole on the Design of an Exploratory Analysis of the AEGEAN Trial in NSCLC

October 7th 2023

David Harpole, MD, discusses on the rationale and design of an exploratory analysis of the phase 3 AEGEAN trial in patients with EGFR-mutated non–small cell lung cancer, which he presented at the 2023 IASLC World Conference on Lung Cancer.

Dr Haffty on the Rationale for Investigating Preoperative Radiation Boosts in Breast Cancer

October 7th 2023

Bruce Haffty, MD, MS, discusses the rationale for launching a clinical trial to assess the feasibility of preoperative radiation boost in patients with breast cancer.

Dr Choueiri on the Benefit of Ongoing Investigations in Metastatic RCC

October 7th 2023

Toni K. Choueiri, MD, discusses the benefit of ongoing investigations in metastatic, advanced renal cell carcinoma.

Dr. Moustafa on Clinical Implications of the BRUIN Trial of Pirtobrutinib in MCL

October 6th 2023

Muhamad Alhaj Moustafa, MD, MS, has improved the treatment of patients with mantle cell lymphoma, and the role that this agent has in the current treatment landscape.

Dr Parrondo on the Clinical Benefit of Momelotinib on Anemia in Myelofibrosis

October 6th 2023

Ricardo D. Parrondo, MD, discusses the clinical benefit seen with momelotinib in anemic myelofibrosis, and where it fits into the current treatment paradigm in this disease landscape.

Dr Aerts on the Rationale for the DENIM Trial in Mesothelioma

October 5th 2023

Joachim G. J. V. Aerts, MD, PhD, discusses the rationale for conducting the phase 3 DENIM trial in patients with mesothelioma, highlighting the importance of focusing investigational efforts onto the dendritic cells.

Dr Usmani on Approaching Treatment Decisions in High-Risk Multiple Myeloma

October 5th 2023

Saad Z. Usmani, MD, MBA, FACP, discusses the complexity of approaching frontline treatment decisions in patients with high-risk multiple myeloma.

Dr Kahl on Ongoing and Planned Investigations Within the Landscape of MCL

October 5th 2023

Brad S. Kahl, MD, discusses ongoing and planned investigations within the landscape of mantle cell lymphoma.

Dr Ikegawa on An Analysis of Rapidly Manufactured Durcabtagene Autoleucel in R/R Multiple Myeloma

October 5th 2023

Shuntaro Ikegawa, MD, PhD, discusses results from a correlative analysis of an ongoing phase 1 trial evaluating the use of a novel T-Charge rapid manufacturing platform for the production of durcabtagene autoleucel CAR T-cells in multiple myeloma.

Dr Haffty on the Feasibility of Preoperative Radiation Boost in Breast Cancer

October 5th 2023

Bruce Haffty, MD, MS, discusses the feasibility of utilizing preoperative radiation boost in patients with breast cancer based on initial results from a phase 2 trial.

Dr Rahimi on Escalating Preoperative, Single-Fraction Ablative Radiation in HR-Positive Breast Cancer

October 4th 2023

Asal Rahimi, MD, MS, discusses initial efficacy results from the expanded cohort of a phase 1 dose-escalation study (NCT04040569) evaluating pre-operative, single fraction stereotactic ablative radiation in early-stage, hormone receptor–positive breast cancer.

Dr Lin on Defining Biomarker-Based Treatment Approaches in NSCLC

October 4th 2023

Edwin Lin, MD, PhD, discusses the utilization of antibody-drug conjugates and the importance of defining biomarker-based approaches for this treatment class in patients with non–small cell lung cancer.

Dr Wander on the Evaluation of Vepdegestrant in ER+/HER2– Breast Cancer

October 4th 2023

Seth Wander, MD, PhD, discusses the evaluation of vepdegestrant (ARV-471), a proteolysis targeting chimera estrogen receptor degrader, in patients with advanced estrogen receptor/HER2-negative breast cancer.

Dr Spira on the Evaluation of Fianlimab Plus Cemiplimab in Advanced Melanoma

October 4th 2023

Alexander I. Spira, MD, PhD, FACP, discusses the evaluation of the LAG-3 inhibitor fianlimab plus cemiplimabin patients with advanced melanoma who were PD-L1 inhibitor–naïve, as seen in the findings from a phase 1 study.

Dr Dhodapkar on the Use of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

October 4th 2023

Madhav V. Dhodapkar, MBBS, discusses efficacy and safety findings from the dose-expansion portion of the phase 2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory multiple myeloma.

Dr Phillips on the Evolving Treatment Landscape in MCL

October 4th 2023

Tycel Phillips, MD, discusses current and emerging therapeutic treatment strategies for patients with mantle cell lymphoma.

O'Neil on the Feasibility of Diagnostic CT-Enabled Planning For Patients Receiving Palliative Radiation Therapy

October 4th 2023

Melissa O'Neil, MRT(T), discusses findings from the randomized phase 2 Diagnostic CT-Enabled Radiation Therapy trial of palliative radiation therapy.

Dr Wong on Hypofractionation vs Conventional Fractionation in Breast Cancer Postmastectomy

October 3rd 2023

Julia S. Wong, MD, discusses findings from data presented on patient-reported toxicity results from the randomized trial of fractionation following breast reconstruction in patients with breast cancer.

Dr Davies on Challenges Experienced When Treating Patients With Multiple Myeloma

October 3rd 2023

Faith E. Davies, MD, discusses challenges experienced by hematologist-oncologists and specialist nurses when treating patients with multiple myeloma.